Biogen outlines 2026 non-GAAP EPS $12-$13 and expects SYFOVRE and EMPAVELI mid- to high teens growth through at least 2028

Biogen's 2026 non-GAAP EPS target of $12-$13 represents approximately 10-15% growth compared to the previous year, confirming stable profitability. The 'mid-to-high growth' outlook for SYFOVRE and EMPAVELI suggests sustained revenue growth potential for the core product line. In particular, the growth plans through 2028 are assessed as a structural growth story that supports long-term valuation increases despite short-term volatility.

Biogen's 2026 non-GAAP EPS target ($12-$13) and the 'mid-to-high growth rate' outlook for SYFOVRE/EMPAVELI represent a continuous growth plan through 2028, which is a clear growth story linking stable cash flow from the product portfolio with the potential for success in new drug development. In particular, the EPS target is likely to exceed market consensus, which could drive short-term stock price increases, and in the long term, an expansion of valuation premium can be anticipated.